CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Utility and Challenges of an Early Invasive Strategy in Patients Resuscitated From Out-of-Hospital Cardiac Arrest Natural History of Spontaneous Coronary Artery Dissection With Spontaneous Angiographic Healing Canadian SCAD Cohort Study: Shedding Light on SCAD From a United Front Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4 Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review

Original Research2019 Jul;12(7):e005103.

JOURNAL:Circ Cardiovasc Qual Outcomes. Article Link

Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients

Shavadia JS, Holmes DN, Thomas L et al. Keywords: 3-year post-MI survivors; β-blocker; elderly; observational study; long-term cardiovascular outcomes

FULL TEXT PDF